Alkahest-logo.png
Alkahest Announces Multiple Presentations at the Society for Neuroscience Annual Meeting
October 08, 2019 07:30 ET | Alkahest, Inc.
SAN CARLOS, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today...
Alkahest-logo.png
Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of Postoperative Recovery Following Primary Hip or Knee Arthroplasty
August 19, 2019 07:30 ET | Alkahest, Inc.
SAN CARLOS, Calif., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today...
Alkahest-logo.png
Alkahest Announces Positive Top-line Data from Phase 2 Study in Mild to Moderate Alzheimer’s Disease 
August 05, 2019 07:30 ET | Alkahest, Inc.
SAN CARLOS, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical-stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today...
Alkahest-logo.png
Alkahest Phase 2a Study AKST4290-202 in Refractory Neovascular AMD meets Primary and Secondary Endpoints
July 29, 2019 07:30 ET | Alkahest, Inc.
SAN CARLOS, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, announced...
Alkahest-logo.png
Alkahest Strengthens Executive Leadership with Appointment of Robert Klein as Chief Business Officer
July 24, 2019 09:35 ET | Alkahest, Inc.
SAN CARLOS, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced...
Alkahest-logo.png
Alkahest to Present New Data from Phase 2a Study of AKST4290 in Refractory Neovascular AMD at the 2019 American Society of Retina Specialists Annual Meeting
July 15, 2019 07:30 ET | Alkahest, Inc.
SAN CARLOS, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today...